Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts

Human Pathology

Volumn 39, Issue 5, 2008, Pages 710-719

  Itatsu, Keita ^a,b   Zen, Yoh ^c   Yamaguchi, Junpei ^a,b   Ohira, Shusaku ^b   Ishikawa, Akira ^b   Ikeda, Hiroko ^a   Sato, Yasunori ^a   Harada, Kenichi ^a   Sasaki, Motoko ^a   Sasaki, Masatoshi ^d   Sakamoto, Hiroya ^e   Nagino, Masato ^b   Nimura, Yuji ^b   Ohta, Tetsuo ^a   Nakanuma, Yasuni ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^d Saiseikai Takaoka Hospital   (Japan)

^e Division of Dermatology   (Japan)

Author keywords

Bile ducts; Cholangiocarcinoma; Matrix metalloproteinase; Papillary carcinoma; Tumor stage

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS;

EID: 42649090423     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.09.016     Document Type: Article

References (35)

1. Nimura Y., Kamiya J., Kondo S., et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 7 (2000) 155-162
2. Nagakawa T., Kayahara M., Ikeda S., et al. Biliary tract cancer treatment: results from the biliary tract cancer. Statistics registry in Japan. J Hepatobiliary Pancreat Surg 9 (2002) 569-575
3. Suh K.S., Roh H.R., Koh Y.T., et al. Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 31 (2000) 12-17
4. Chen T.C., Nakanuma Y., Zen Y., et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 34 (2001) 651-658
5. Tajima Y., Kuroki T., Fukuda K., et al. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg. 91 (2004) 99-104
6. Shibahara H., Tamada S., Higashi M., et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 39 (2004) 220-229
7. Miwa S., Miyagawa S., Soeda J., et al. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer 94 (2002) 428-434
8. Jarnagin W.R., Bowne W., Klimstra D.S., et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 241 (2005) 703-714
9. Suto T., Sugai T., Nakamura S., et al. Immunohistochemical detection of proliferating cell nuclear antigen and p53 expression in carcinoma of the extrahepatic bile duct. Oncology 54 (1997) 407-413
10. Takao S., Uchikura K., Yonezawa S., et al. Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis. Cancer 86 (1999) 1966-1975
11. Sugimachi K., Aishima S., Taguchi K., et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol 35 (2001) 74-79
12. Hui A.M., Cui X., Makuuchi M., et al. Decreased p27 (Kip1) expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology 30 (1999) 1167-1173
13. Albores-Saavedra J., Murakata L., Krueger J.E., et al. Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts. Cancer 89 (2000) 508-515
14. Hoang M.P., Murakata L.A., Katabi N., et al. Invasive papillary carcinomas of extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol 15 (2002) 1251-1258
15. Hong S.M., Cho H.J., Lee O.J., et al. The number of metastatic lymph nodes in extrahepatic bile duct carcinoma as a prognostic factor. Am J Surg Pathol 29 (2005) 1177-1183
16. Zen Y., Sasaki M., Fujii T., et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct-an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 44 (2006) 350-358
17. Zen Y., Fujii T., Itatsu K., et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44 (2006) 1333-1343
18. Deryugina E.I., and Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25 (2006) 9-34
19. Ii M., Yamamoto H., Adachi Y., et al. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 231 (2006) 20-27
20. Yamashita K., Mori M., Shiraishi T., et al. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 6 (2000) 1169-1174
21. Yamamoto H., Itoh F., Iku S., et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 19 (2001) 1118-11127
22. Jiang W.G., Davies G., Martin T.A., et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 17 (2006) 583-590
23. Maatta M., Soini Y., Liakka A., et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6 (2000) 2726-2734
24. Shirabe K., Shimada M., Kajiyama K., et al. Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. Surgery 126 (1999) 842-846
25. Sato H., Takino T., Okada Y., et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (Lond) 370 (1994) 61-65
26. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Letters 194 (2003) 1-11
27. Itatsu K., Zen Y., Ohira S., et al. Immmunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int 27 (2007) 1144-1184
28. Zen Y., Aishima S., Ajioka Y., et al. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement. Pathol Int 55 (2005) 180-188
29. Nakanuma Y., Hoso M., Sanzen T., et al. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech 38 (1997) 552-570
30. International Union Against Cancer UICC. TNM classification of malignant tumors. 6th ed. (2002), Wiley-Liss, New York
31. Albores-Saavedra J., Menck H.R., Scoazec J.C., et al. Carcinoma of the gallbladder and extrahepatic bile ducts. In: Hamilton S.R., and Aaltonen L.A. (Eds). World Health Organization Classification of Tumours, Pathology and Genetics: Tumours of the Digestive systems (2000), IARC Press, Lyon (France) 206-214
32. Chae K.J., Rha S.Y., Oh B.K., et al. Expression of matrix metalloproteinase-2 and-9 and tissue inhibitor of metalloproteinase-1 and-2 in intraductal and nonintraductal growth type of cholangiocarcinoma. Am J Gastroenterology 99 (2004) 68-75
33. Terada T., Okada Y., and Nakanuma Y. Expression of immunoreactive matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 23 (1996) 1341-1344
34. King J., Zhao J., Clingan P., et al. Randomized double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 23 (2003) 639-645
35. Bramhall S.R., Hallissey M.T., Whiting J., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomized trial. Br J Cancer 86 (2002) 1864-1870